MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Salon.com
August 30, 2000
Arthur Allen
Portrait of a drug czar Gen. Barry McCaffrey drives his government office like a lockstep battalion, but some contend his ruthless schedule and egomaniacal ways are only hurting his effort to bring sanity to America's drug policy. mark for My Articles similar articles
Reason
Aug/Sep 2001
Jacob Sullum
Bad Timing "The Drug War Worked Once. It Can Again." So read the headline above William J. Bennett's May 15 defense of drug czar nominee John Walters in The Wall Street Journal... mark for My Articles similar articles
The Motley Fool
May 26, 2011
Brian Orelli
Congress Sets Bad Precedent With AVANIR What happened to free markets? mark for My Articles similar articles
Salon.com
May 12, 2001
Katharine Mieszkowski
What has Barry McCaffrey been smoking? The former drug czar goes dot-com with an Internet company that charges $1,200 for online drug treatment... mark for My Articles similar articles
Salon.com
September 1, 2000
Arianna Huffington
An eerie campaign silence Bush and Gore should tell us where they stand on the ugly $1.3 billion drug war offensive in Colombia that the next president will have to face. mark for My Articles similar articles
Chemistry World
November 2010
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? mark for My Articles similar articles
The Motley Fool
July 12, 2010
Ryan McBride
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. mark for My Articles similar articles
The Motley Fool
February 28, 2011
Brian Orelli
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. mark for My Articles similar articles
The Motley Fool
February 16, 2010
Brian Orelli
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. mark for My Articles similar articles
The Motley Fool
July 28, 2010
Jordan DiPietro
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage mark for My Articles similar articles
Reason
March 2001
Michael W. Lynch
D.C. Downers In which our man in Washington listens to the drug czar babble and learns why we can't afford tax cuts... mark for My Articles similar articles
Chemistry World
March 2011
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations mark for My Articles similar articles
Salon.com
July 27, 2000
Daniel Forbes
Fighting "Cheech & Chong" medicine Did the White House drug office go too far in trying to stop the spread of medical marijuana initiatives? mark for My Articles similar articles
Chemistry World
July 16, 2010
Matt Wilkinson
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. mark for My Articles similar articles
Salon.com
June 30, 2001
Daniel Forbes
The quiet death of prime-time propaganda With no fanfare, the White House drug office pulls the plug on its controversial program to pay TV networks for putting anti-drug messages in popular shows... mark for My Articles similar articles
The Motley Fool
January 21, 2011
Brian Orelli
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. mark for My Articles similar articles
Reason
January 2004
Renee Moilanen
Just Say No Again The old failures of new and improved anti-drug education mark for My Articles similar articles
The Motley Fool
May 21, 2010
Brian Orelli
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. mark for My Articles similar articles
The Motley Fool
March 30, 2011
Sean Williams
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps. mark for My Articles similar articles
The Motley Fool
April 7, 2011
Brian Orelli
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. mark for My Articles similar articles
The Motley Fool
July 30, 2010
Brian Orelli
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. mark for My Articles similar articles
The Motley Fool
July 30, 2010
Brian Orelli
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. mark for My Articles similar articles
The Motley Fool
June 25, 2010
Brian Orelli
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. mark for My Articles similar articles
The Motley Fool
March 31, 2011
Brian Orelli
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. mark for My Articles similar articles
The Motley Fool
December 31, 2010
Brian Orelli
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. mark for My Articles similar articles
The Motley Fool
January 12, 2010
Dayana Yochim
6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2011
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. mark for My Articles similar articles
The Motley Fool
March 4, 2010
Brian Orelli
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. mark for My Articles similar articles
The Motley Fool
September 30, 2010
Brian Orelli
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. mark for My Articles similar articles
The Motley Fool
January 8, 2010
Brian Orelli
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. mark for My Articles similar articles
The Motley Fool
September 28, 2010
Brian Orelli
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. mark for My Articles similar articles
The Motley Fool
September 24, 2010
Brian Orelli
Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front. mark for My Articles similar articles
The Motley Fool
December 3, 2010
Brian Orelli
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. mark for My Articles similar articles
The Motley Fool
June 29, 2010
Brian Orelli
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. mark for My Articles similar articles
The Motley Fool
November 30, 2010
Brian Orelli
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. mark for My Articles similar articles
Salon.com
January 9, 2001
Arianna Huffington
The right stuff President-elect Bush should make reform-minded New Mexico Gov. Gary Johnson his drug czar... mark for My Articles similar articles
The Motley Fool
January 28, 2010
Brian Orelli
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. mark for My Articles similar articles
The Motley Fool
January 29, 2010
Brian Orelli
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. mark for My Articles similar articles
The Motley Fool
September 8, 2010
Jim Mueller
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. mark for My Articles similar articles
The Motley Fool
February 26, 2011
Brian Orelli
FDA Applications and a Look Ahead It isn't pretty. mark for My Articles similar articles
Salon.com
August 28, 2000
Ana Arana
Cleaning up for Clinton The fortress tourist town of Cartagena banned street children and demonstrations on the eve of the president's arrival. mark for My Articles similar articles
The Motley Fool
March 8, 2010
Brian Orelli
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. mark for My Articles similar articles
Salon.com
April 20, 2001
Daniel Forbes
Bush's new drug czar? John Walters, a hard-line drug warrior, is the leading candidate to replace Barry McCaffrey. Advocates say he's a throwback to the bad old days of Bill Bennett... mark for My Articles similar articles
The Motley Fool
January 25, 2010
Brian Orelli
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. mark for My Articles similar articles
The Motley Fool
April 22, 2011
Sean Williams
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. mark for My Articles similar articles
The Motley Fool
December 30, 2010
Brian Orelli
This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly. mark for My Articles similar articles
Salon.com
February 22, 2000
Michael Massing
The elephant in the room Presidential candidates are silent on the failure of the U.S. war on drugs. mark for My Articles similar articles
BusinessWeek
January 21, 2010
John Carey
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. mark for My Articles similar articles
BusinessWeek
March 11, 2010
Ellen Gibson
The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL. mark for My Articles similar articles
Salon.com
October 10, 2000
Arthur Allen
The drug war's Tweedledee Does National Institute on Drug Abuse chief Alan Leshner push propaganda over science in his close coordination with drug czar Barry McCaffrey? mark for My Articles similar articles